October 31, 2018 / 10:15 PM / 15 days ago

BRIEF-Roche Holding AG - Randomized Phase III CLL14 Study Met Its Primary Endpoint

Oct 31 (Reuters) - Roche Holding AG:

* PHASE III DATA SHOWED THAT VENCLEXTA PLUS GAZYVA REDUCED THE RISK OF DISEASE WORSENING OR DEATH IN PEOPLE WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA WITH CO-MORBIDITIES

* ROCHE HOLDING AG - DATA WILL BE SUBMITTED TO HEALTH AUTHORITIES AND PRESENTED AT AN UPCOMING MEDICAL MEETING

* ROCHE HOLDING AG - RANDOMIZED PHASE III CLL14 STUDY SHOWED A STATISTICALLY SIGNIFICANT REDUCTION IN RISK OF DISEASE WORSENING OR DEATH

* ROCHE HOLDING AG - RANDOMIZED PHASE III CLL14 STUDY MET ITS PRIMARY ENDPOINT Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below